2023-508280-69-00已完成1 期
A Phase 1 Study of BMS-986406 as Monotherapy and in Combination in Advanced Tumors
Bristol Myers Squibb International Corporation, Bristol Myers Squibb International Corporation11 个研究点 分布在 2 个国家目标入组 27 人开始时间: 2024年1月9日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 27
- 试验地点
- 11
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Head of the GSM-CT
Scientific
Bristol Myers Squibb International Corporation
研究点 (11)
Loading locations...
相似试验
招募中
2 期
A Phase 1/2 Study of BMS-986408 with and without Nivolumab or Nivolumab and Ipilimumab in Participants with Solid Tumors2022-500823-61-00Bristol-Myers Squibb International Corporation34
招募中
1 期
A Phase 1 Study of BMS-986453 in Participants with Relapsed and/or Refractory Multiple Myeloma2023-506003-26-00Celgene Corp.19
招募中
1 期
A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986521 in Healthy Participants.NCT07283263Bristol-Myers Squibb106
招募中
2 期
A Phase 1/2 Study of BMS-986458 Alone and in Combination with Anti-lymphoma Agents in Relapsed/Refractory NHL2023-506654-20-00Bristol-Myers Squibb Services Unlimited Company166
招募中
3 期
An Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Moderate-to-Severe Plaque Psoriasis2022-502361-15-00Bristol Myers Squibb International Corporation664